Asset
VOSORITIDE
BioMarin Pharmaceutical Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04554940 | phase2 | active_not_recruiting | 2020-10-10 | 2027-12-01 | BioMarin Pharmaceutical | A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia |
| NCT03583697 | phase2 | completed | 2018-06-13 | 2022-01-26 | BioMarin Pharmaceutical | A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia |
| NCT02055157 | phase2 | completed | 2014-01-13 | 2017-10-02 | BioMarin Pharmaceutical | A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia |
| NCT06382155 | phase2 | recruiting | 2024-10-21 | 2026-06-01 | BioMarin Pharmaceutical | A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature |
| NCT07126262 | phase2 | recruiting | 2025-07-30 | 2028-06-30 | BioMarin Pharmaceutical | A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 214938 | NDA | BIOMARIN PHARMACEUTICAL INC |
Marketed products (3)
- VOXZOGO
- VOXZOGO
- VOXZOGO